130 related articles for article (PubMed ID: 8385592)
1. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative.
Hoover WW; Gerlach EH; Hoban DJ; Eliopoulos GM; Pfaller MA; Jones RN
Diagn Microbiol Infect Dis; 1993 Feb; 16(2):111-8. PubMed ID: 8385592
[TBL] [Abstract][Full Text] [Related]
2. In vitro antimicrobial activity of tioconazole and its concentrations in vaginal fluids following topical (vagistat-1 6.5%) application.
Jones RN; Bale MJ; Hoban D; Erwin ME
Diagn Microbiol Infect Dis; 1993 Jul; 17(1):45-51. PubMed ID: 8359005
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of rifaximin, a topical rifamycin derivative, against Chlamydia trachomatis.
Prasad ES; Wenman WM
Diagn Microbiol Infect Dis; 1993 Feb; 16(2):135-6. PubMed ID: 8467625
[TBL] [Abstract][Full Text] [Related]
4. Rifaximin, a peculiar rifamycin derivative: established and potential clinical use outside the gastrointestinal tract.
Pelosini I; Scarpignato C
Chemotherapy; 2005; 51 Suppl 1():122-30. PubMed ID: 15855757
[TBL] [Abstract][Full Text] [Related]
5. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis.
Brigidi P; Swennen E; Rizzello F; Bozzolasco M; Matteuzzi D
J Chemother; 2002 Jun; 14(3):290-5. PubMed ID: 12120885
[TBL] [Abstract][Full Text] [Related]
6. [Susceptibility of major pathogens of acute pharyngitis and tonsillitis to levofloxacin and other oral antimicrobial drugs].
Matsuzaki K; Yoshimori K; Shikano M; Watabe E; Sato Y; Hasegawa M; Kobayashi I; Yamanaka N
Jpn J Antibiot; 2003 Jun; 56(3):171-9. PubMed ID: 12942788
[TBL] [Abstract][Full Text] [Related]
7. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).
Jones RN; Barry AL
Diagn Microbiol Infect Dis; 1989; 12(6):495-510. PubMed ID: 2560422
[TBL] [Abstract][Full Text] [Related]
8. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
[TBL] [Abstract][Full Text] [Related]
9. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.
Gillis JC; Brogden RN
Drugs; 1995 Mar; 49(3):467-84. PubMed ID: 7774516
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species.
Marchese A; Salerno A; Pesce A; Debbia EA; Schito GC
Chemotherapy; 2000; 46(4):253-66. PubMed ID: 10859431
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth.
Pistiki A; Galani I; Pyleris E; Barbatzas C; Pimentel M; Giamarellos-Bourboulis EJ
Int J Antimicrob Agents; 2014 Mar; 43(3):236-41. PubMed ID: 24461710
[TBL] [Abstract][Full Text] [Related]
12. Rifaximin--a novel antimicrobial for enteric infections.
Huang DB; DuPont HL
J Infect; 2005 Feb; 50(2):97-106. PubMed ID: 15667909
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
[TBL] [Abstract][Full Text] [Related]
14. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci.
DuPont HL; Jiang ZD
Clin Microbiol Infect; 2004 Nov; 10(11):1009-11. PubMed ID: 15522005
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of rifaximin against clinical isolates of Escherichia coli and other enteropathogenic bacteria isolated from travellers returning to the UK.
Hopkins KL; Mushtaq S; Richardson JF; Doumith M; de Pinna E; Cheasty T; Wain J; Livermore DM; Woodford N
Int J Antimicrob Agents; 2014 May; 43(5):431-7. PubMed ID: 24661532
[TBL] [Abstract][Full Text] [Related]
16. Antibacterial activity of rokitamycin compared with that of other macrolides.
Yu KW; Briones F; Chin NX; Neu HC
Diagn Microbiol Infect Dis; 1991; 14(4):331-5. PubMed ID: 1889182
[TBL] [Abstract][Full Text] [Related]
17. Rifaximin intake leads to emergence of rifampin-resistant staphylococci.
Valentin T; Leitner E; Rohn A; Zollner-Schwetz I; Hoenigl M; Salzer HJ; Krause R
J Infect; 2011 Jan; 62(1):34-8. PubMed ID: 21073894
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of CP-74667 compared with four other fluoroquinolones.
Jones RN; Erwin ME
Diagn Microbiol Infect Dis; 1992 Aug; 15(6):531-6. PubMed ID: 1330419
[TBL] [Abstract][Full Text] [Related]
19. Formulation of 'idealized' topical antimicrobial mixtures for use with cultured skin grafts.
Holder IA; Boyce ST
J Antimicrob Chemother; 1996 Sep; 38(3):457-63. PubMed ID: 8889720
[TBL] [Abstract][Full Text] [Related]
20. Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations.
Debbia EA; Maioli E; Roveta S; Marchese A
J Chemother; 2008 Apr; 20(2):186-94. PubMed ID: 18467244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
